UBS Group’s MEDGENICS INC WT PUR COM EXP 03/31/16 MDGN.WS Stock Holding History

UBS Group’s Portfolio MDGN.WS Stock Details MDGN.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-20	Closed	–	–	9171
2015 Q1	$0	Sell	20 -3,799	-99%	-$9.73K	﹤0.01%	9905
2014 Q4	$10K	Buy	+3,819	New	+$5.54K	﹤0.01%	8437

Other funds holding MDGN.WS

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

UBS Group's MDGN.WS Position: Q2 2015 in Review

UBS Group sold out of MEDGENICS INC WT PUR COM EXP 03/31/16 (MDGN.WS) in Q2 2015, closing a stake of 20 shares.

UBS Group first reported a position in MDGN.WS in Q4 2014 and held it in 2 quarters. The position peaked at $10K in Q4 2014. 2 funds tracked by Wall St. Rank hold MDGN.WS as of Q2 2015.

UBS Group reported no remaining MEDGENICS INC WT PUR COM EXP 03/31/16 position as of Q2 2015 after selling out during the quarter.
UBS Group sold 20 MEDGENICS INC WT PUR COM EXP 03/31/16 shares in Q2 2015.
UBS Group first reported a position in MEDGENICS INC WT PUR COM EXP 03/31/16 in Q4 2014 and held it in 2 quarters.
UBS Group's MEDGENICS INC WT PUR COM EXP 03/31/16 position peaked at $10K in Q4 2014.
2 funds tracked by Wall St. Rank held MEDGENICS INC WT PUR COM EXP 03/31/16 as of Q2 2015.

Based on UBS Group's 13F filing for Q2 2015, filed 14 Aug 2015.